Navigation Links
Novus Scientific and Singapore Association of Plastic Surgeons (SAPS) Host the Inaugural Event of 'SOFTISSUE - The Issue of Soft Tissue,' Featuring James J. Chao, M.D., FACS, Professor of Plastic Surgery and Orthopedic Surgery, University of Califor
Date:11/3/2010

SINGAPORE, Nov. 3, 2010 /PRNewswire/ -- Singapore company Novus Scientific Pte. Ltd today announced the successful hosting of Asia's 1st "SOFTISSUE – The Issue of Soft Tissue" educational series, together with the Singapore Association of Plastic Surgeons (SAPS) on 1st November 2010.

This inaugural event featured James J. Chao, M.D., FACS, who spoke on "Technological Innovations in Plastic Surgery," which focused on the latest advances in breast reconstruction & fat grafting. Dr. Chao is currently Professor of Plastic Surgery and Orthopedic Surgery at the University of California, San Diego (UCSD) Medical Centre. Attendees consisted of Plastic & General Surgeons from Singapore and the region, as well as select government agencies and members of the health media. The venue was at the Novus Restaurant, housed in the historical National Museum of Singapore.

"I am honored to be invited as the 1st speaker of SOFTISSUE, as it provides not only a great platform for U.S. Plastic Surgeons such as myself to interact and share clinical best practices with surgeons of SAPS, but also an opportunity to collaborate on future clinical studies, which may bring tremendous benefits to patients worldwide," said James J. Chao, M.D., FACS, Professor of Plastic Surgery & Professor of Orthopedic Surgery, (UCSD).

"Novus Scientific is a proud supporter of the 1st SOFTISSUE, together with SAPS, which brings together the top Plastic, Aesthetic and Reconstructive Surgeons in Singapore and the U.S. for an educational meeting of minds," said Thomas Engstrom, CEO & President of Novus Scientific. "We plan to bring SOFTISSUE to the U.S. as well as to Europe and beyond in the years to come."

Novus Scientific is currently supporting a clinical study on TRAM Flap donor site reinforcement using TIGR® Matrix Surgical Mesh. Asia's first patient was enrolled on 21st October 2010 at the National University Hospital Singapore. Link http://bit.ly/btihfu

TIGR® Matrix is the World's 1st Long-Term Resorbable Synthetic Mesh. U.S. FDA cleared TIGR® Matrix Surgical Mesh for use in reinforcement of soft tissues where weakness exists in February 2010.

About Novus Scientific

Novus Scientific (www.novusscientific.com) is an innovator in the development and commercialization of resorbable synthetic medical devices. Global HQ is in Singapore while European Headquarters and the core R&D function are in Uppsala, Sweden. The company's roots are Swedish as all the founders of Novus Scientific are previous owners / senior managers / members of the soft tissue-engineering project within Uppsala-based, Radi Medical Systems AB (now owned by St. Jude Medical Inc). The US Division, Novus Scientific, Inc. is headquartered near Boston, one of the world's foremost medical research cities. From this hub, Novus Scientific, Inc. will distribute TIGR® Matrix Surgical Mesh throughout the United States.

TIGR® is a trademark of Novus Scientific Pte. Ltd

Media contact: Tac-Whei Ong (tacwhei.ong@novusscientific.com) - tel: +65 9179 6661


'/>"/>
SOURCE Novus Scientific Pte. Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - Worlds 1st Long-Term Resorbable Synthetic Mesh
2. Novus Scientific Announces the Sales Launch for TIGR™ Matrix Surgical Mesh - Worlds 1st Long-Term Resorbable Synthetic Mesh
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
5. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
6. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
7. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
8. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
9. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
10. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
11. Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
(Date:10/5/2017)... , Oct. 5, 2017  In response to ... Oral and Maxillofacial Surgeons (AAOMS) released prescribing recommendations ... to be used as a first-line therapy to ... Recognizing the value ... White Paper "Opioid Prescribing: Acute and Postoperative Pain ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, a family ... and Raleigh regions, is organizing an extended charity drive to benefit the family ... abnormality. , After struggling since birth with several health challenges, T.J. was later ...
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to ... Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed a ... or restricted lighting. As such, it eliminates the need to turn on a light ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading ... Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly ... CBD form that can be easily incorporated into liquid products, while reducing costs to ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton ... staged a mock evacuation of the facility as part of a disaster drill on ... Echo Hose EMS and Shelton City Emergency Manager, as well as the Connecticut ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
Breaking Medicine News(10 mins):